Fenofibric Acid
NDC Package 0115-1554-10
Package Information
Fenofibric Acid is delayed release capsules are contraindicated in:patients with severe renal impairment, including those receiving dialysis [see Clinical Pharmacology (12.3)].patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions (5.3)].patients with preexisting gallbladder disease [see Warnings and Precautions (5.5)].nursing mothers [see Use in Specific Populations (8.3)].patients with hypersensitivity to fenofibric acid or fenofibrate [see Warnings and Precautions (5.9)]. Marketed by Amneal Pharmaceuticals Of New York Llc, this product is identified by NDC 0115-1554 and is authorized under FDA application NDA022224.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0115 - Amneal Pharmaceuticals Of New York Llc
- 0115-1554 - Fenofibric Acid
- 0115-1554-10 - 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE
- 0115-1554 - Fenofibric Acid
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0115-1554-10 identifies a specific commercial package of 90 capsule, delayed release in 1 bottle of Fenofibric Acid, labeled by Amneal Pharmaceuticals Of New York Llc. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Amneal Pharmaceuticals Of New York Llc on September 12, 2016. The current certification is valid through July 31, 2026.
How is this Amneal Pharmaceuticals Of New York Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00115155410. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 90 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.